

Search done by Bill Mercier  
(No access to the Internet on 1-20-04)

STN Results: 1-1 CAPLUS IBIB ABS FHITST


10/089, 167

1 ANSWERS PRINTED IN FORMAT 'IBIB ABS FHITSTR HITRN'

IN FILE 'CAPLUS'

USING QUERY:

L5 STR



Structure attributes must be viewed using STN Express query preparation.

L7 278 SEA FILE=REGISTRY SSS FUL L5

L8 1 SEA FILE=CAPLUS L7

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN

Full Text

ACCESSION NUMBER: 2001:247320 CAPLUS

DOCUMENT NUMBER: 134:280851

TITLE: Quinazolinones useful as glycoprotein IbIX antagonists, and their preparation and use for control of thrombotic disorders

INVENTOR(S): Mederski, Werner; Devant, Ralf; Barnickel, Gerhard; Bernotat-danielowski, Sabine; Melzer, Guido; Dhanoa, Daljit; Zhao, Bao-ping; Rinker, James; Player, Mark; Soll, Richard

PATENT ASSIGNEE(S): Merck Patent GmbH, Germany; et al.

SOURCE: PCT Int. Appl., 64 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023364	A1	20010405	WO 2000-EP8939	20000913
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
BR 2000014311	A	20020521	BR 2000-14311	20000913
EP 1216233	A1	20020626	EP 2000-962482	20000913
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,			

## STN Results: 1-1 CAPLUS IBIB ABS FHITST

PT, IE, SI, LT, LV, FI, RO, MK, CY, AL



NO 2002001503 A 20020326 NO 2002-1503 20020326

PRIORITY APPLN. INFO.: US 1999-407939 A 19990928

WO 2000-EP8939 W 20000913

OTHER SOURCE(S): MARPAT 134:280851

GI



AB Quinazolinones I and their pharmaceutically tolerable salts and solvates are disclosed [in which R, R1 = H, A, OH, OA, OCH<sub>2</sub>Ar, Hal, NH<sub>2</sub>, NHA, NA<sub>2</sub>, NO<sub>2</sub>, cyano, COR<sub>2</sub>, CONH<sub>2</sub>, CONHA, CONA<sub>2</sub>, CO<sub>2</sub>H, CO<sub>2</sub>A, SO<sub>2</sub>A; R<sub>2</sub>, R<sub>3</sub> = H, A, C(:NH)NH<sub>2</sub>, solid phase; R<sub>4</sub> = Ar, phenylalkyl, cycloalkyl, Het; Y = bond, C<sub>2</sub>-4 alkylene; A = (un)branched C<sub>1</sub>-6 alkyl; Ar = (un)substituted Ph, naphthyl, biphenyl, or benzofuranyl; Het = (un)substituted, (un)satd. mono- or bicyclic NOS heterocycl; Hal = F, Cl, Br, or iodo; n, m = 0-3]. The compds. are glycoprotein IbIX antagonists (no data), useful for treatment or prophylaxis of a variety of thrombotic disorders, or as anti-adhesive substances for implants, catheters, or heart pacemakers. For instance, an exemplary amine, [3-(aminomethyl)cyclohexyl]methylamine, was supported on p-nitrophenyl carbonate resin, then coupled with various Fmoc-protected anthranilic acids. Cleavage of the Fmoc group, cyclocondensation with various aldehydes R<sub>4</sub>CHO, oxidn. of the resultant dihydroquinazolinone ring system, and cleavage from the resin with CF<sub>3</sub>CO<sub>2</sub>H, gave a variety of compds. I, e.g., the preferred compd. II.


IT 332120-80-6P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-phenyl-3H-quinazolin-4-one

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of quinazolinone derivs. as glycoprotein IbIX antagonists)

RN 332120-80-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-phenyl- (9CI) (CA INDEX NAME)



IT 332120-80-6P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-phenyl-3H-quinazolin-4-one 332120-81-7P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-chloro-2-phenyl-3H-quinazolin-4-one 332120-82-8P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methyl-2-phenyl-3H-quinazolin-4-one 332120-83-9P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-7-chloro-2-phenyl-3H-quinazolin-4-one 332120-84-0P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methoxy-2-phenyl-3H-quinazolin-4-one 332120-85-1P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-chloro-2-(2-methylphenyl)-3H-quinazolin-4-one 332120-86-2P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methyl-2-(2-methylphenyl)-3H-quinazolin-4-one 332120-87-3P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-7-chloro-2-(2-methylphenyl)-3H-quinazolin-4-one 332120-88-4P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methoxy-2-(2-methylphenyl)-3H-quinazolin-4-one 332120-89-5P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-(2-methylphenyl)-3H-quinazolin-4-one 332120-90-8P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-chloro-2-(3-methylphenyl)-3H-quinazolin-4-one 332120-91-9P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methyl-2-(3-methylphenyl)-3H-quinazolin-4-one 332120-92-0P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-7-chloro-2-(3-methylphenyl)-3H-quinazolin-4-one 332120-93-1P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methoxy-2-(3-methylphenyl)-3H-quinazolin-4-one 332120-94-2P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-(3-methylphenyl)-3H-quinazolin-4-one 332120-95-3P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-chloro-2-(4-methylphenyl)-3H-quinazolin-4-one 332120-96-4P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methyl-2-(4-methylphenyl)-3H-quinazolin-4-one 332120-97-5P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-7-chloro-2-(4-methylphenyl)-3H-quinazolin-4-one 332120-98-6P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methoxy-2-(4-methylphenyl)-3H-quinazolin-4-one 332120-99-7P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-(4-methylphenyl)-3H-quinazolin-4-one 332121-00-3P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-chloro-2-(4-tert-butylphenyl)-3H-quinazolin-4-one 332121-02-5P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methyl-2-(4-tert-butylphenyl)-3H-quinazolin-4-one 332121-03-6P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-7-chloro-2-(4-tert-butylphenyl)-3H-quinazolin-4-one 332121-04-7P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methoxy-2-(4-tert-butylphenyl)-3H-quinazolin-4-one 332121-05-8P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-(4-tert-butylphenyl)-3H-quinazolin-4-one 332121-06-9P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-chloro-2-(3-chlorophenyl)-3H-quinazolin-4-one 332121-07-0P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methyl-2-(3-chlorophenyl)-3H-quinazolin-4-one 332121-08-1P, 3-[[3-

STN Results: 1-1 CAPLUS IBIB ABS FHITST

(Aminomethyl)cyclohexyl]methyl]-7-chloro-2-(3-chlorophenyl)-3H-quinazolin-4-one **332121-09-2P**, 3-[[3-  
(Aminomethyl)cyclohexyl]methyl]-6-methoxy-2-(3-chlorophenyl)-3H-quinazolin-4-one **332121-10-5P**, 3-[[3-  
(Aminomethyl)cyclohexyl]methyl]-2-(3-chlorophenyl)-3H-quinazolin-4-one **332121-11-6P**, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-chloro-2-(4-methoxyphenyl)-3H-quinazolin-4-one **332121-12-7P**, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methyl-2-(4-methoxyphenyl)-3H-quinazolin-4-one **332121-13-8P**, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-7-chloro-2-(4-methoxyphenyl)-3H-quinazolin-4-one **332121-14-9P**, 3-[[3-  
(Aminomethyl)cyclohexyl]methyl]-6-methoxy-2-(4-methoxyphenyl)-3H-quinazolin-4-one **332121-15-0P**, 3-[[3-  
(Aminomethyl)cyclohexyl]methyl]-2-(4-methoxyphenyl)-3H-quinazolin-4-one **332121-16-1P**, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-chloro-2-(3-methoxyphenyl)-3H-quinazolin-4-one **332121-17-2P**, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methyl-2-(3-methoxyphenyl)-3H-quinazolin-4-one **332121-18-3P**, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-7-chloro-2-(3-methoxyphenyl)-3H-quinazolin-4-one **332121-19-4P**, 3-[[3-  
(Aminomethyl)cyclohexyl]methyl]-6-methoxy-2-(3-methoxyphenyl)-3H-quinazolin-4-one **332121-20-7P**, 3-[[3-  
(Aminomethyl)cyclohexyl]methyl]-2-(3-methoxyphenyl)-3H-quinazolin-4-one **332121-21-8P**, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-[2,2']bithiophenyl-5-yl-6-chloro-3H-quinazolin-4-one **332121-22-9P**, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-[2,2']bithiophenyl-5-yl-6-methyl-3H-quinazolin-4-one **332121-23-0P**, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-[2,2']bithiophenyl-5-yl-7-chloro-3H-quinazolin-4-one **332121-24-1P**, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-[2,2']bithiophenyl-5-yl-6-methoxy-3H-quinazolin-4-one **332121-25-2P**, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-[2,2']bithiophenyl-5-yl-3H-quinazolin-4-one **332121-26-3P**, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-chloro-2-(2-furan-2-ylvinyl)-3H-quinazolin-4-one **332121-27-4P**, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methyl-2-(2-furan-2-ylvinyl)-3H-quinazolin-4-one **332121-28-5P**, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-7-chloro-2-(2-furan-2-ylvinyl)-3H-quinazolin-4-one **332121-29-6P**, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methoxy-2-(2-furan-2-ylvinyl)-3H-quinazolin-4-one **332121-30-9P**, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-(2-furan-2-ylvinyl)-3H-quinazolin-4-one **332121-31-0P**, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-chloro-2-cyclohexyl-3H-quinazolin-4-one **332121-32-1P**, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methyl-2-cyclohexyl-3H-quinazolin-4-one **332121-33-2P**, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-7-chloro-2-cyclohexyl-3H-quinazolin-4-one **332121-34-3P**, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methoxy-2-cyclohexyl-3H-quinazolin-4-one **332121-35-4P**, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-cyclohexyl-3H-quinazolin-4-one **332121-36-5P**, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-chloro-2-(2-phenylethyl)-3H-quinazolin-4-one **332121-37-6P**, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methyl-2-(2-phenylethyl)-3H-quinazolin-4-one **332121-38-7P**, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-7-chloro-2-(2-phenylethyl)-3H-quinazolin-4-one **332121-39-8P**, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methoxy-2-(2-phenylethyl)-3H-quinazolin-4-one **332121-40-1P**, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-(2-phenylethyl)-3H-quinazolin-4-

STN Results: 1-1 CAPLUS IBIB ABS FHITST

one 332121-41-2P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-biphenyl-4-yl-6-chloro-3H-quinazolin-4-one 332121-42-3P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-biphenyl-4-yl-6-methyl-3H-quinazolin-4-one 332121-43-4P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-biphenyl-4-yl-7-chloro-3H-quinazolin-4-one 332121-44-5P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-biphenyl-4-yl-6-methoxy-3H-quinazolin-4-one 332121-45-6P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-biphenyl-4-yl-3H-quinazolin-4-one 332121-46-7P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-thiophen-3-yl-6-chloro-3H-quinazolin-4-one 332121-47-8P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-thiophen-3-yl-6-methyl-3H-quinazolin-4-one 332121-48-9P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-thiophen-3-yl-7-chloro-3H-quinazolin-4-one 332121-49-0P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-thiophen-3-yl-6-methoxy-3H-quinazolin-4-one 332121-50-3P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-thiophen-3-yl-3H-quinazolin-4-one 332121-51-4P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-thiophen-2-yl-6-chloro-3H-quinazolin-4-one 332121-52-5P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-thiophenyl-2-yl-6-methyl-3H-quinazolin-4-one 332121-53-6P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-thiophen-2-yl-7-chloro-3H-quinazolin-4-one 332121-54-7P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-thiophen-2-yl-6-methoxy-3H-quinazolin-4-one 332121-55-8P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-thiophen-2-yl-3H-quinazolin-4-one 332121-56-9P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-naphthalen-2-yl-6-chloro-3H-quinazolin-4-one 332121-57-0P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-naphthalen-2-yl-6-methyl-3H-quinazolin-4-one 332121-58-1P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-naphthalen-2-yl-7-chloro-3H-quinazolin-4-one 332121-59-2P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-naphthalen-2-yl-6-methoxy-3H-quinazolin-4-one 332121-60-5P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-naphthalen-2-yl-3H-quinazolin-4-one 332121-61-6P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-naphthalen-1-yl-6-chloro-3H-quinazolin-4-one 332121-62-7P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-naphthalen-1-yl-6-methyl-3H-quinazolin-4-one 332121-63-8P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-naphthalen-1-yl-7-chloro-3H-quinazolin-4-one 332121-64-9P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-naphthalen-1-yl-6-methoxy-3H-quinazolin-4-one 332121-65-0P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-naphthalen-1-yl-3H-quinazolin-4-one 332121-66-1P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-styryl-6-chloro-3H-quinazolin-4-one 332121-67-2P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-styryl-6-methyl-3H-quinazolin-4-one 332121-68-3P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-styryl-7-chloro-3H-quinazolin-4-one 332121-69-4P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-styryl-6-methoxy-3H-quinazolin-4-one 332121-70-7P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-styryl-3H-quinazolin-4-one 332121-71-8P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-benzofuran-5-yl-6-methyl-3H-quinazolin-4-one 332121-72-9P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-benzofuran-5-yl-6-methyl-3H-quinazolin-4-one 332121-73-0P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-benzofuran-5-yl-7-chloro-3H-quinazolin-4-one 332121-74-1P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-benzofuran-5-yl-6-methoxy-3H-

STN Results: 1-1 CAPLUS IBIB ABS FHITST

quinazolin-4-one 332121-75-2P, 3-[(3-  
(Aminomethyl)cyclohexyl)methyl]-2-benzofuran-5-yl-3H-quinazolin-4-  
one 332121-76-3P, 3-[(3-(Aminomethyl)cyclohexyl)methyl]-2-  
[2-(4-dimethylaminophenyl)vinyl]-6-chloro-3H-quinazolin-4-one  
332121-77-4P, 3-[(3-(Aminomethyl)cyclohexyl)methyl]-2-[2-(4-  
dimethylaminophenyl)vinyl]-6-methyl-3H-quinazolin-4-one  
332121-78-5P, 3-[(3-(Aminomethyl)cyclohexyl)methyl]-2-[2-(4-  
dimethylaminophenyl)vinyl]-7-chloro-3H-quinazolin-4-one  
332121-79-6P, 3-[(3-(Aminomethyl)cyclohexyl)methyl]-2-[2-(4-  
dimethylaminophenyl)vinyl]-6-methoxy-3H-quinazolin-4-one  
332121-80-9P, 3-[(3-(Aminomethyl)cyclohexyl)methyl]-2-[2-(4-  
dimethylaminophenyl)vinyl]-3H-quinazolin-4-one

RL: BAC (Biological activity or effector, except adverse); BSU  
(Biological study, unclassified); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation);  
USES (Uses)

(drug candidate; prepn. of quinazolinone derivs. as glycoprotein  
IbIX antagonists)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE  
FOR THIS RECORD. ALL CITATIONS AVAILABLE  
IN THE RE FORMAT

L Number	Hits	Search Text	DB	Time stamp
1	641	((514/266.3) or (514/266.31) or (544/287)).CCLS.	USPAT; US-PGPUB	2004/01/20 16:42
2	200	((514/266.3) or (514/266.31) or (544/287)).CCLS.) and cyclohexyl	USPAT; US-PGPUB	2004/01/20 16:42

EAST  
10/089, 167